• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Is AtriCure on the auction block? | Wall Street Beat

Is AtriCure on the auction block? | Wall Street Beat

October 17, 2011 By MassDevice staff

MassDevice.com Wall Street Beat

AtriCure Inc. (NSDQ:ATRC) could be poised for a buyout over the next year to 18 months, according to Canaccord Genuity analyst Jason Mills.

"We like the company’s leadership position in the surgical atrial fibrillation market currently, and we also favor the company’s new product and clinical trial pipeline," Mills wrote in a note investors. "Both make us optimistic the company can produce double-digit growth for a while. We also see ATRC as a potential take-out candidate over the next 12-18 months."

Mills named four other medical device firms the investment advisor has his eye on: HeartWare International (NSDQ:HTWR) and arch-rival (and onetime suitor) Thoratec Corp. (NSDQ:THOR), Spectranetics (NSDQ:SPNC) and Volcano Corp. (NSDQ:VOLC):

Sign up to get our free newsletters delivered right to your inbox

"We continue to believe HTWR will achieve leading outside the United States in 2011 and number one worldwide share by 2015. We would be buyers of HTWR at current levels."

"We continue to believe the lead management business is worth the stock’s current valuation on its own, noting its growth profile, high barriers to entry, low penetration, and SPNC’s leadership position."

"For long-term investors, we recommend targeting a slightly lower entry point to accumulate THOR."

"We have a favorable view of the company’s revenue growth trajectory and are encouraged by improving operating leverage. However for now remain on the sidelines looking for a better entry point."

Is Zoll’s growth for real?

Zoll Medical (NSDQ:ZOLL) is carrying more than $100 million worth of goodwill and intangibles on its balance sheet, prompting Rex Moore of the Motley Fool website to flag the company’s stock.

"Zoll Medical carries $104.5 million of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it’s excessive, can foreshadow problems down the road. Could this be the case with Zoll Medical?," asked Moore, an associate analyst for Motley Fool Hidden Gems.

Taking a close look at a pair of metrics used to gauge the risk of an AOL-Time Warner-esque implosion – intangible assets ratio and tangible book value – Moore concludes that ZOLL shares deserve a "yellow flag."

Intangible assets ratio is the percentage of total assets made up by goodwill and other intangibles. An IAR score of 20 percent or more should give investors pause, according to Moore; Zoll’s score is 24 percent, not a cause for panic "but you’ll want to keep an eye on this number over the next few quarters," according to the analyst.

Tangible book value is what’s left after calculating IAR. A negative score is bad because it can indicate that a company lacks the resources to remain competitive during a recession or in the face of competition. Zoll’s TBV is $247.7 million, "so no yellow flag here," Moore wrote.
Read more

Analyst: Stryker & Zimmer likely to please The Street

Stryker Corp. (NYSE:SYK) and Zimmer Holdings (NYSE:ZMH) are likely to meet or beat Wall Street estimates for their third-quarter results, according to RBC Capital Markets analyst Glenn Novarro.

"Stability in U.S. hospital capital spending and the orthopedic markets will help both Stryker Corp. and Zimmer Holdings Inc. meet analyst expectations for the third quarter, and that could boost company shares, The Associated Press reported.
Read more

RBC reiterates Becton, Dickinson rating

RBC Capital reiterated its "sector perform" rating for Becton, Dickinson & Co. (NYSE:BDX)setting a rpcie target of $75.
Read more

Analogic earns upgrade

TheStreet.com upgraded its rating on shares of Analogic Corp. (NSDQ:ALOG), citing the MRI pioneer’s "revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance,"

"We feel these strengths outweigh the fact that the company has had sub-par growth in net income," the analysts wrote.
Read more

Filed Under: News Well, Wall Street Beat Tagged With: Analogic, AtriCure Inc., becton dickinson, Cardiac Rhythm Management, Stryker, Zimmer Biomet, Zoll Medical

More recent news

  • Data backs DermaSensor skin cancer detection device
  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy